Clinical trial

Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases

NCT02398526

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2015-03-19

PhaseN/A

Study timeline

Study start (actual)2015-03-19Date precision: day

Registry last updated2021-11-02

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Castration-Resistant Prostatic Cancerunresolved

Interventions

Radium-223 dichloride, (Xofigo, BAY88-8223)DRUG

Sponsors & collaborators

Bayerlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02398526 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.